Nothing Special   »   [go: up one dir, main page]

WO2000063192A1 - Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them - Google Patents

Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them Download PDF

Info

Publication number
WO2000063192A1
WO2000063192A1 PCT/IB2000/000470 IB0000470W WO0063192A1 WO 2000063192 A1 WO2000063192 A1 WO 2000063192A1 IB 0000470 W IB0000470 W IB 0000470W WO 0063192 A1 WO0063192 A1 WO 0063192A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenoxazin
ethoxy
phenyl
ethoxypropanoic acid
arginine salt
Prior art date
Application number
PCT/IB2000/000470
Other languages
French (fr)
Inventor
Om Reddy Gaddam
Rajender Kumar Potlapally
Raju Sirisilla
Vyas Krishnamurthi
Sreenivasa Rao Dharmaraja
Ramabhadra Sarma Mamillapalli
Original Assignee
Dr. Reddy's Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1999/000681 external-priority patent/WO2000063191A1/en
Priority to EEP200100529A priority Critical patent/EE200100529A/en
Priority to AU38313/00A priority patent/AU3831300A/en
Priority to MXPA01010472A priority patent/MXPA01010472A/en
Priority to IL14595800A priority patent/IL145958A0/en
Priority to CA002370401A priority patent/CA2370401A1/en
Application filed by Dr. Reddy's Research Foundation filed Critical Dr. Reddy's Research Foundation
Priority to EP00917222A priority patent/EP1171430A1/en
Priority to BR0010683-6A priority patent/BR0010683A/en
Priority to JP2000612284A priority patent/JP2003508348A/en
Publication of WO2000063192A1 publication Critical patent/WO2000063192A1/en
Priority to HR20010748A priority patent/HRP20010748A2/en
Priority to NO20015016A priority patent/NO20015016L/en
Priority to BG106022A priority patent/BG106022A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • This invention relates to novel polymorphic / pseudopolymorphic forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, preferably, L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I shown below.
  • the invention also relates to a , pharmaceutical composition comprising the novel polymorphic form or their mixture and a pharmaceutically acceptable carrier.
  • polymorphic forms of the present invention are more active, as antidiabetic and hypolipidemic agent, than the novel 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
  • the present invention also relates to a process for the preparation of novel polymorphic / pseudopolymorphic Forms of arginine salt of 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula (I).
  • the polymorphic Forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, of formula (I) defined above of the present invention lower total cholesterol (TC); increase high density lipoprotein (HDL) and decrease low density lipoprotein (LDL), which have a beneficial effect on coronary heart disease and atherosclerosis.
  • TC total cholesterol
  • HDL high density lipoprotein
  • LDL low density lipoprotein
  • novel polymorphic Forms of arginine salt of 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of formula (I) defined above of the present invention are useful in reducing body weight and for the treatment and/or prophylaxis of diseases such as hypertension, coronary heart disease, atherosclerosis, stroke, peripheral vascular diseases and related disorders.
  • These novel polymorphic Forms compounds are useful for the treatment of familial hypercholesterolemia, hypertriglyceridemia, lowering of atherogenic lipoproteins, NLDL (very low density lipoprotein) and LDL.
  • novel polymorphic Forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, of formula (I) of the present invention can be used for the treatment of certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis and nephropathy.
  • novel polymorphic Forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, of formula (I) are also useful for the treatment and/or prophylaxis of insulin resistance (type II diabetes), leptin resistance, impaired glucose tolerance, dyslipidemia, disorders related to syndrome X such as hypertension, obesity, insulin resistance, coronary heart disease and other cardiovascular disorders.
  • novel polymorphic Forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, of formula (I) may also be useful as aldose reductase inhibitors, for improving cognitive functions in dementia, treating diabetic complications, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), inflammatory bowel diseases, osteoporosis, myotonic dystrophy, pancreatitis, arteriosclerosis, retinopathy, xanthoma, inflammation and for the treatment of cancer.
  • PCOS polycystic ovarian syndrome
  • novel polymorphic Forms of arginine salt of 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of formula (I) of the present invention are useful in the treatment and/or prophylaxis of the above said diseases in combination/con-comittant with one or more HMG CoA reductase inhibitors, hypolipidemic/ hypolipoproteinemic agents such as fibric acid derivatives, nicotinic acid, cholestyramine, colestipol, probucol.
  • HMG CoA reductase inhibitors hypolipidemic/ hypolipoproteinemic agents
  • fibric acid derivatives such as fibric acid derivatives, nicotinic acid, cholestyramine, colestipol, probucol.
  • Atherosclerosis and other peripheral vascular diseases are the major causes effecting the quality of life of millions of people. Therefore, considerable attention has been directed towards understanding the etiology of hypercholesterolemia and hyperlipidemia and development of effective therapeutic strategies.
  • Hypercholesterolemia has been defined as plasma cholesterol level that exceeds arbitrarily defined value called “normal” level. Recently, it has been accepted that "ideal" plasma levels of cholesterol are much below the "normal” level of cholesterol in the general population and the risk of coronary artery disease (CAD) increases as cholesterol level rises above the "optimum” (or “ideal”) value. There is clearly a definite cause and effect-relationship between hypercholesterolemia and CAD, particularly for individuals with multiple risk factors. Most of the cholesterol is present in the esterified forms with various lipoproteins such as Low density lipoprotein (LDL), intermediate density lipoprotein (IDL), High density lipoprotein (HDL) and partially as Very low density lipoprotein (NLDL).
  • LDL Low density lipoprotein
  • IDL intermediate density lipoprotein
  • HDL High density lipoprotein
  • NLDL Very low density lipoprotein
  • Obesity is a disease highly prevalent in affluent societies and in the developing world and is a major cause of morbidity and mortality. It is a state of excess body fat accumulation. The causes of obesity are unclear. It is believed to be of genetic origin or promoted by an interaction between the genotype and environment. Irrespective of the cause, the result is fat deposition due to imbalance between the energy intake versus energy expenditure. Dieting, exercise and appetite suppression have been a part of obesity treatment. There is a need for efficient therapy to fight this disease since it may lead to coronary heart disease, diabetes, stroke, hyperlipidemia, gout, osteoarthritis, reduced fertility and many other psychological and social problems.
  • Diabetes and insulin resistance is yet another disease which severely effects the quality of a large population in the world. Insulin resistance is the diminished ability of insulin to exert its biological action across a broad range of concentrations. In insulin resistance, the body secretes abnormally high amounts of insulin to compensate for this defect; failing which, the plasma glucose concentration inevitably rises and develops into diabetes.
  • diabetes mellitus is a common problem and is associated with a variety of abnormalities including obesity, hypertension, hyper- lipidemia (J. Clin. Invest., (1985) 75 : 809 - 817; N. Engl. J. Med. (1987) 317: 350-357; J. Clin. Endocrinol. Metab., (1988) 66 : 580 - 583; J.
  • Hyperlipidemia is the primary cause for cardiovascular (CVD) and other peripheral vascular diseases.
  • High risk of CVD is related to the higher LDL (Low Density Lipoprotein) and NLDL (Very Low Density Lipoprotein) seen in hyperlipidemia.
  • LDL Low Density Lipoprotein
  • NLDL Very Low Density Lipoprotein
  • Patients having glucose intolerance/insulin resistance in addition to hyperlipidemia have higher risk of CVD.
  • Numerous studies in the past have shown that lowering of plasma triglycerides and total cholesterol, in particular LDL and VLDL and increasing HDL cholesterol help in preventing cardiovascular diseases.
  • Peroxisome proliferator activated receptors are members of the nuclear receptor super family.
  • PPAR ⁇ The gamma ( ⁇ ) isoform of PPAR (PPAR ⁇ ) has been implicated in regulating differentiation of adipocytes (Endocrinology, (1994) 135: 798-800) and energy homeostasis (Cell, (1995) 83: 803-812), whereas the alpha ( ⁇ ) isoform of PPAR (PPAR ⁇ ) mediates fatty acid oxidation (Trend. Endocrin. Metab., (1993) 4: 291-296) thereby resulting in reduction of circulating free fatty acid in plasma (Current Biol.
  • PPAR ⁇ agonists have been found useful for the treatment of obesity (WO 97/36579). It has been recently disclosed that there exists synergism for the molecules, which are agonists for both PPAR ⁇ and PPAR ⁇ and suggested to be useful for the treatment of syndrome X (WO 97/25042). Similar synergism between the insulin sensitizer (PPAR ⁇ agonist) and HMG CoA reductase inhibitor has been observed which may be useful for the treatment of atherosclerosis and xanthoma (EP 0 753 298). It is known that PPAR ⁇ plays an important role in adipocyte differentiation (Cell,
  • PPAR ⁇ is consistently expressed in certain cells and activation of this nuclear receptor with PPAR ⁇ agonists would stimulate the terminal differentiation of adipocyte precursors and cause morphological and molecular changes characteristics of a more differentiated, less malignant state (Molecular Cell, (1998), 465-470; Carcinogenesis, (1998), 1949-53; Proc. Natl. Acad. Sci., (1997) 94, 237-241) and inhibition of expression of prostate cancer tissue (Cancer Research (1998) 58:3344-3352). This would be useful in the treatment of certain types of cancer, which express PPAR ⁇ and could lead to a quite nontoxic chemotherapy.
  • Leptin resistance is a condition wherein the target cells are unable to respond to leptin signal. This may give rise to obesity due to excess food intake and reduced energy expenditure and cause impaired glucose tolerance, type 2 diabetes, cardiovascular diseases and such other interrelated complications.
  • Kallen et al Proc. Natl. Acad. Sci. (1996) 93, 5793-5796) have reported that insulin sensitizers which perhaps due to the PPAR agonist expression and therefore lower plasma leptin concentrations.
  • compounds having insulin sensitizing property also possess leptin sensitization activity. They lower the circulating plasma leptin concentrations by improving the target cell response to leptin (WO/98/02159).
  • polymorphism we mean to include different physical forms, crystal forms, crystalline / liquid crystalline / non-crystalline (amorphous) forms. This has especially become very interesting after observing that many antibiotics, antibacterials, tranquilizers etc., exhibit polymorphism and some/one of the polymorphic forms of a given drug exhibit superior bio-availability and consequently show much higher activity compared to other polymorphs.
  • Sertraline, Frentizole, Ranitidine, Sulfathiazole, Indomethacine etc. are some of the important examples of pharmaceuticals which exhibit polymorphism.
  • Another objective of the present invention is to provide polymorphic forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, their stereoisomers, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures which may have agonist activity against PPAR ⁇ and/or PPAR ⁇ , and optionally inhibit HMG CoA reductase, in addition to having agonist activity against PPAR ⁇ and/or PPAR ⁇ .
  • Another objective of the present invention is to provide novel polymorphic forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, their stereoisomers, pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures having enhanced activities, without toxic effect or with reduced toxic effect.
  • the pharmaceutical salts of the compounds of the general formula (a) includes salts of the organic bases such as guanine, arginine, guanidine, diethylamine, choline, and the like. Particularly the compounds disclosed include 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
  • the present invention relates to an observation that arginine salt of 3-[4-[2-(phenoxazin- 10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid exhibits polymorphism, which has not been reported till date.
  • the polymorphic Forms I, II, III, IV and V are obtained from different solvents like isopropyl alcohol, acetone, 1,4-dioxane, dimethylsulphoxide, and dimethylformamide respectively.
  • Form VI is obtained by dissolving any form (Form I- V) in water and freeze drying.
  • Form VII is obtained by dissolving any form (Form I-V) in methanol and quick evaporation of the solvent under reduced pressure at 40-60 °C.
  • Form VIII is obtained by refluxing Form-I in 1,4-dioxane.
  • Form-IX is obtained by refluxing Form- VIII in isopropyl alcohol.
  • Form X is prepared by heating Form I to 185 °C and cooling it to room temperature.
  • Form XI is prepared by heating Form X to 175 °C and cooling it to room temperature.
  • DSC of the polymorphic Form I shows melting endotherm at 181 °C.
  • Form II displays endotherms at 131 °C, 166 °C, 178 °C, 214 °C and 276 °C and exotherms at 169 °C.
  • Form III exhibits melting endotherm 182 °C in addition to an exotherm at 168 °C.
  • Form IV exhibits endotherms at 149 °C, 164 °C and 185 °C and an exotherm at 171 °C.
  • Form V exhibits endotherms at 119 °C, 164 °C, 172 °C and 185 °C in addition to a melting exotherm at 173 °C.
  • Form VI exhibits exotherm at 157 °C and endotherms at 179 °C and 183 °C.
  • Form VII exhibits exotherm at 132 °C and endotherms at 176 °C and 184 °C.
  • Form VIII there was a similar exotherm of Form VI at 158 °C and the melting endotherm at 178 °C, whereas in Form IX there was only one sharp melting endotherm at 176 °C.
  • Form X displays an exotherm at 163 °JC. and melting endotherm at 184 °C.
  • Form XI exhibits a melting endotherm at 184 °C.
  • X-ray powder diffraction pattern has been obtained on a Rigaku D/Max 2200 model diffractometer equiped with horizontal gonimometer in ⁇ /2 ⁇ geometry.
  • Fig. 1 is a characteristic X-ray powder diffraction pattern of Form I.
  • Fig. 2 is a characteristic X-ray powder diffraction pattern of Form II.
  • Fig. 3 is a characteristic X-ray powder diffraction pattern of Form III.
  • Fig. 4 is a characteristic X-ray powder diffraction pattern of Form IV.
  • Fig. 5 is a characteristic X-ray powder diffraction pattern of Form V.
  • Fig. 6 is a characteristic X-ray powder diffraction pattern of Form VI.
  • Fig. 7 is a characteristic X-ray powder diffraction pattern of Form VII.
  • Fig. 8 is a characteristic X-ray powder diffraction pattern of Form VIII.
  • Fig. 9 is a characteristic X-ray powder diffraction pattern of Form IX.
  • Fig. 10 is a characteristic X-ray powder diffraction pattern of Form X.
  • Fig. 11 is a characteristic X-ray powder diffraction pattern of Form XL
  • Fig. 12 is a characteristic X-ray powder diffraction pattern of polymorphic form mixture.
  • Differential scanning calorimeter was performed on a Shimadzu DSC-50 equipped with a controller. The data was collected on to a Pentium PC using a Shimadzu TA-50 software. The samples weighed in aluminum cells were heated from room temperature to 220 °C at a heating rate of 5 °C /min. The empty aluminum cell was used as a reference. Dry nitrogen gas was purged through DSC cell continuously throughout the analysis at a flow of 30 ml/min.
  • Fig. 13 is a characteristic differential scanning calorimetric thermogram of Form I.
  • Fig. 14 is a characteristic differential scanning calorimetric thermogram of Form II.
  • Fig. 15 is a characteristic differential scanning calorimetric thermogram of Form III.
  • Fig. 16 is a characteristic differential scanning calorimetric thermogram of Form IV.
  • Fig. 17 is a characteristic differential scanning calorimetric thermogram of Form V.
  • Fig. 18 is a characteristic differential scanning calorimetric thermogram of Form VI.
  • Fig. 19 is a characteristic differential scanning calorimetric thermogram of Form VII.
  • Fig. 20 is a characteristic differential scanning calorimetric thermogram of Form VIII.
  • Fig. 21 is a characteristic differential scanning calorimetric thermogram of Form IX.
  • Fig. 22 is a characteristic differential scanning calorimetric thermogram of Form X.
  • Fig. 23 is a characteristic differential scanning calorimetric thermogram of Form XI.
  • Fig. 24 is a characteristic differential scanning calorimetric thermogram of polymorphic form mixture.
  • Fig. 25 is a characteristic infrared absorption spectrum of Form I in KBr.
  • Fig. 26 is a characteristic infrared absorption spectrum of Form II in KBr.
  • Fig. 27 is a characteristic infrared absorption spectrum of Form III in KBr.
  • Fig. 28 is a characteristic infrared absorption spectrum of Form IV in KBr.
  • Fig. 29 is a characteristic infrared absorption spectrum of Form V in KBr.
  • Fig. 30 is a characteristic infrared absorption spectrum of Form VI in KBr.
  • Fig. 31 is a characteristic infrared absorption spectrum of Form VII in KBr.
  • Fig. 32 is a characteristic infrared absorption spectrum of Form VIII in KBr.
  • Fig. 33 is a characteristic infrared absorption spectrum of Form IX in KBr.
  • Fig. 34 is a characteristic infrared absorption spectrum of Form X in KBr.
  • Fig. 35 is a characteristic infrared absorption spectrum of Form XI in KBr.
  • Fig. 36 is a characteristic infrared absorption spectrum of polymorphic form mixture in KBr.
  • Infrared absorption bands (cm "1 ): 3061, 1710, 1588, 1510, 1491, 1379, 1273,
  • a novel polymorphic Form-V of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid having the formula I which is characterized by the following data : DSC: Endotherm at 185.95 °C, (onset at 178.09 °C) (Fig -17) Small endotherms at 119.81 °C, 164.69 °C, 172.44 °C Small exotherm at 173.82 °C
  • Infrared absorption bands (cm "1 ): 3266, 3055, 1711, 1589, 1510, 1492, 1379, 1274, 1175, 1111, 1040, 918, 819, 730, 676, 544, (Fig -29)
  • the temperature employed in the stirring step (iii) may be preferably 40-50 °C.
  • step (iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-
  • step (iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, (vi) heating the polymo ⁇ hic Form-I obtained in step (v) to 185 °C and cooling it to room temperature to yeild Form-X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid and
  • step (vii) heating the polymo ⁇ hic Form-X obtained in step (vi) to 175 °C and cooling it to room temperature to yield Form-XI of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
  • step (iv) filtering the white crystalline powder obtained in step (iii) and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield mixture of polymo ⁇ hic Form of I and X of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
  • the organic solvents are selected from acetonitrile, ethanol, methanol and, isopropanol.
  • the present invention also envisages a pharmaceutical composition
  • a pharmaceutical composition comprising a polymo ⁇ hic Forms I to XI of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of the formula (I) or the mixture of polymo ⁇ hic Form of I and X and a pharmaceutically acceptable carrier .
  • the present invention also envisages a pharmaceutical composition
  • a pharmaceutical composition comprising a mixture of any of polymo ⁇ hic Forms I to XI of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of the formula (I) and a pharmaceutically acceptable carrier .
  • the pharmaceutical composition may be in the forms normally employed, such as tablets, capsules, powders, syrups, solutions, suspensions and the like, may contain flavourants, sweeteners etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions.
  • Such compositions typically contain from 1 to 25 %, preferably 1 to 15 % by weight of active ingredient, the remainder of the composition being pharmaceutically acceptable carriers, diluents or solvents.
  • polymo ⁇ hic forms of the formula (I) as defined above are clinically administered to mammals, including man, via either oral, nasal, pulmonary, transdermal or parenteral, rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment.
  • Administration by the oral route is preferred, being more convenient and avoiding the possible pain and irritation of injection.
  • the patient cannot swallow the medication, or abso ⁇ tion following oral administration is impaired, as by disease or other abnormality, it is essential that the drug be administered parenterally.
  • the dosage is in the range of about 0.01 to about 100 mg / kg body weight of the subject per day or preferably about 0.01 to about 30 mg / kg body weight per day administered singly or as a divided dose.
  • the optimum dosage for the individual subject being treated will be determined by the person responsible for treatment, generally smaller doses being administered initially and thereafter increments made to determine the most suitable dosage.
  • Suitable pharmaceutically acceptable carriers include solid fillers or diluents and sterile aqueous or organic solutions.
  • the active ingredient will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above.
  • the polymo ⁇ hic form can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like.
  • the pharmaceutical compositions may, if desired, contain additional components such as flavourants, sweeteners, excipients and the like.
  • the polymo ⁇ hic form can be combined with sterile aqueous or organic media to form injectable solutions or suspensions.
  • solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically- acceptable acid addition salts or salts with base of the compounds.
  • Aqueous solutions with the active ingredient dissolved in polyhydroxylated castor oil may also be used for injectable solutions.
  • the injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.
  • the preparation may contain the polymo ⁇ hic forms of the present invention dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application.
  • a liquid carrier in particular an aqueous carrier
  • the carrier may contain additives such as solubilizing agents, such as propylene glycol, surfactants, abso ⁇ tion enhancers such as lecithin (phosphatidylcholine) or cyclodextrin or preservatives such as parabenes.
  • Tablets, dragees or capsules having talc and / or a carbohydrate carried binder or the like are particularly suitable for any oral application.
  • carriers for tablets, dragees or capsules include lactose, corn starch and / or potato starch.
  • a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
  • the ingredients 1 to 3 are uniformly blended with water and granulated after drying under reduced pressure.
  • the ingredient 4 and 5 are mixed well with the granules and compressed by a tabletting machine to prepare 1000 tablets each containing 30 mg of active ingredient.
  • ingredients 1-4 are uniformly moistened with an aqueous solution of 5 and granulated after drying under reduced pressure.
  • Ingredient 6 is added and granules are compressed by a tabletting machine to prepare 1000 tablets containing 30 mg of ingredient 1.
  • Examples 1-4 illustrates the process for the preparation of the polymorphic Form-1 of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid,
  • Example-1
  • Example 6 Process for the preparation of the polymorphic Form-II of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
  • Example 7 Process for the preparation of the polymorphic Form-Ill of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
  • Example 8 Process for the preparation of the polymorphic Form-IV of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
  • Example 9 Process for the preparation of the polymorphic Form-V of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
  • Example 10 Process for the preparation of the polymorphic Form-VI of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
  • Example 11 Process for the preparation of the polymorphic Form-VII of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
  • Example 12 Process for the preparation of the polymorphic form- VIII of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, Polymo ⁇ hic Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1 g), obtained by the process described in Example-2 above was refluxed in 1,4-dioxane (10 ml), filtered and dried under vacuum to yield Form- VIII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]- 2-ethoxypropanoic acid which has the characteristics given earlier.
  • Example 13 Process for the preparation of the polymorphic Form-IX of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
  • Example 14 Process for the preparation of the polymorphic Form-X of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
  • Example 15 Process for the preparation of the polymorphic Form-XI of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, Polymo ⁇ hic Form-X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid obtained by the process described in Example 14 was heated to 175 °C and cooled it to room temperature to yield Form-XI of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid which has the characteristics given earlier.
  • Example 16 Process for the preparation of mixture of polymorphic Forms I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid,
  • Example 17 Process for the preparation of polymorphic Form I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

This invention relates to novel polymorphic/pseudopolymorphic forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having formula (I). The invention also relates to a pharmaceutical composition comprising the novel polymorphic form or their mixture and a pharmaceutically acceptable carrier. The polymorphic forms of the present invention are more active, as antidiabetic and hypolipidemic agent, than the novel 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid.

Description

NOVEL POLYMORPHIC FORMS OF AN ANTIDIABETIC AGENT : PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Background of the invention
This invention relates to novel polymorphic / pseudopolymorphic forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, preferably, L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I shown below. The invention also relates to a , pharmaceutical composition comprising the novel polymorphic form or their mixture and a pharmaceutically acceptable carrier. The polymorphic forms of the present invention are more active, as antidiabetic and hypolipidemic agent, than the novel 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
Figure imgf000003_0001
The present invention also relates to a process for the preparation of novel polymorphic / pseudopolymorphic Forms of arginine salt of 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula (I).
The polymorphic Forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, of formula (I) defined above of the present invention lower total cholesterol (TC); increase high density lipoprotein (HDL) and decrease low density lipoprotein (LDL), which have a beneficial effect on coronary heart disease and atherosclerosis. The novel polymorphic Forms of arginine salt of 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of formula (I) defined above of the present invention are useful in reducing body weight and for the treatment and/or prophylaxis of diseases such as hypertension, coronary heart disease, atherosclerosis, stroke, peripheral vascular diseases and related disorders. These novel polymorphic Forms compounds are useful for the treatment of familial hypercholesterolemia, hypertriglyceridemia, lowering of atherogenic lipoproteins, NLDL (very low density lipoprotein) and LDL. The novel polymorphic Forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, of formula (I) of the present invention can be used for the treatment of certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis and nephropathy. The novel polymorphic Forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, of formula (I) are also useful for the treatment and/or prophylaxis of insulin resistance (type II diabetes), leptin resistance, impaired glucose tolerance, dyslipidemia, disorders related to syndrome X such as hypertension, obesity, insulin resistance, coronary heart disease and other cardiovascular disorders. These novel polymorphic Forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, of formula (I) may also be useful as aldose reductase inhibitors, for improving cognitive functions in dementia, treating diabetic complications, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), inflammatory bowel diseases, osteoporosis, myotonic dystrophy, pancreatitis, arteriosclerosis, retinopathy, xanthoma, inflammation and for the treatment of cancer. The novel polymorphic Forms of arginine salt of 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of formula (I) of the present invention are useful in the treatment and/or prophylaxis of the above said diseases in combination/con-comittant with one or more HMG CoA reductase inhibitors, hypolipidemic/ hypolipoproteinemic agents such as fibric acid derivatives, nicotinic acid, cholestyramine, colestipol, probucol. Background of the invention
Atherosclerosis and other peripheral vascular diseases are the major causes effecting the quality of life of millions of people. Therefore, considerable attention has been directed towards understanding the etiology of hypercholesterolemia and hyperlipidemia and development of effective therapeutic strategies.
Hypercholesterolemia has been defined as plasma cholesterol level that exceeds arbitrarily defined value called "normal" level. Recently, it has been accepted that "ideal" plasma levels of cholesterol are much below the "normal" level of cholesterol in the general population and the risk of coronary artery disease (CAD) increases as cholesterol level rises above the "optimum" (or "ideal") value. There is clearly a definite cause and effect-relationship between hypercholesterolemia and CAD, particularly for individuals with multiple risk factors. Most of the cholesterol is present in the esterified forms with various lipoproteins such as Low density lipoprotein (LDL), intermediate density lipoprotein (IDL), High density lipoprotein (HDL) and partially as Very low density lipoprotein (NLDL). Studies clearly indicate that there is an inverse correlationship between CAD and atherosclerosis with serum HDL-cholesterol concentrations. (Stampfer et al, N. Engl. J. Med., 325 (1991), 373-381) and the risk of CAD increases with increasing levels of LDL and NLDL. In CAD, generally "fatty streaks" in carotid, coronary and cerebral arteries, are found which are primarily free and esterified cholesterol. Miller et al, (Br. Med. J., 282 (1981), 1741 - 1744) have shown that increase in HDL-particles may decrease the number of sites of stenosis in coronary arteries of human, and high level of HDL- cholesterol may protect against the progression of atherosclerosis. Picardo et al, (Arteriosclerosis 6 (1986) 434 - 441) have shown by in vitro experiment that HDL is capable of removing cholesterol from cells. They suggest that HDL may deplete tissues of excess free cholesterol and transfer it to liver (Macikinnon et al, J. Biol. chem. 261 (1986), 2548 - 2552). Therefore, agents that increase HDL cholesterol would have therapeutic significance for the treatment of hypercholesterolemia and coronary heart diseases (CHD).
Obesity is a disease highly prevalent in affluent societies and in the developing world and is a major cause of morbidity and mortality. It is a state of excess body fat accumulation. The causes of obesity are unclear. It is believed to be of genetic origin or promoted by an interaction between the genotype and environment. Irrespective of the cause, the result is fat deposition due to imbalance between the energy intake versus energy expenditure. Dieting, exercise and appetite suppression have been a part of obesity treatment. There is a need for efficient therapy to fight this disease since it may lead to coronary heart disease, diabetes, stroke, hyperlipidemia, gout, osteoarthritis, reduced fertility and many other psychological and social problems.
Diabetes and insulin resistance is yet another disease which severely effects the quality of a large population in the world. Insulin resistance is the diminished ability of insulin to exert its biological action across a broad range of concentrations. In insulin resistance, the body secretes abnormally high amounts of insulin to compensate for this defect; failing which, the plasma glucose concentration inevitably rises and develops into diabetes. Among the developed countries, diabetes mellitus is a common problem and is associated with a variety of abnormalities including obesity, hypertension, hyper- lipidemia (J. Clin. Invest., (1985) 75 : 809 - 817; N. Engl. J. Med. (1987) 317: 350-357; J. Clin. Endocrinol. Metab., (1988) 66 : 580 - 583; J. Clin. Invest., (1975) 68 : 957 - 969) and other renal complications (See Patent Application No. WO 95/21608). It is now increasingly being recognized that insulin resistance and relative hyperinsulinemia have a contributory role in obesity, hypertension, atherosclerosis and type 2 diabetes mellitus. The association of insulin resistance with obesity, hypertension and angina has been described as a syndrome having insulin resistance as the central pathogenic link- Syndrome-X.
Hyperlipidemia is the primary cause for cardiovascular (CVD) and other peripheral vascular diseases. High risk of CVD is related to the higher LDL (Low Density Lipoprotein) and NLDL (Very Low Density Lipoprotein) seen in hyperlipidemia. Patients having glucose intolerance/insulin resistance in addition to hyperlipidemia have higher risk of CVD. Numerous studies in the past have shown that lowering of plasma triglycerides and total cholesterol, in particular LDL and VLDL and increasing HDL cholesterol help in preventing cardiovascular diseases. Peroxisome proliferator activated receptors (PPAR) are members of the nuclear receptor super family. The gamma (γ) isoform of PPAR (PPARγ) has been implicated in regulating differentiation of adipocytes (Endocrinology, (1994) 135: 798-800) and energy homeostasis (Cell, (1995) 83: 803-812), whereas the alpha (α) isoform of PPAR (PPARα) mediates fatty acid oxidation (Trend. Endocrin. Metab., (1993) 4: 291-296) thereby resulting in reduction of circulating free fatty acid in plasma (Current Biol.
(1995) 5: 618 -621). PPARα agonists have been found useful for the treatment of obesity (WO 97/36579). It has been recently disclosed that there exists synergism for the molecules, which are agonists for both PPARα and PPARγ and suggested to be useful for the treatment of syndrome X (WO 97/25042). Similar synergism between the insulin sensitizer (PPARγ agonist) and HMG CoA reductase inhibitor has been observed which may be useful for the treatment of atherosclerosis and xanthoma (EP 0 753 298). It is known that PPARγ plays an important role in adipocyte differentiation (Cell,
(1996) 87, 377-389). Ligand activation of PPAR is sufficient to cause complete terminal differentiation (Cell, (1994) 79, 1147-1156) including cell cycle withdrawal. PPARγ is consistently expressed in certain cells and activation of this nuclear receptor with PPARγ agonists would stimulate the terminal differentiation of adipocyte precursors and cause morphological and molecular changes characteristics of a more differentiated, less malignant state (Molecular Cell, (1998), 465-470; Carcinogenesis, (1998), 1949-53; Proc. Natl. Acad. Sci., (1997) 94, 237-241) and inhibition of expression of prostate cancer tissue (Cancer Research (1998) 58:3344-3352). This would be useful in the treatment of certain types of cancer, which express PPARγ and could lead to a quite nontoxic chemotherapy.
Leptin resistance is a condition wherein the target cells are unable to respond to leptin signal. This may give rise to obesity due to excess food intake and reduced energy expenditure and cause impaired glucose tolerance, type 2 diabetes, cardiovascular diseases and such other interrelated complications. Kallen et al (Proc. Natl. Acad. Sci. (1996) 93, 5793-5796) have reported that insulin sensitizers which perhaps due to the PPAR agonist expression and therefore lower plasma leptin concentrations. However, it has been recently disclosed that compounds having insulin sensitizing property also possess leptin sensitization activity. They lower the circulating plasma leptin concentrations by improving the target cell response to leptin (WO/98/02159). The latest trend that has, of late, crept into the pharmaceutical industry is the studies on polymorphism in drugs and the difference in the activity of different polymorphic forms of a given drug. By the term polymorphism we mean to include different physical forms, crystal forms, crystalline / liquid crystalline / non-crystalline (amorphous) forms. This has especially become very interesting after observing that many antibiotics, antibacterials, tranquilizers etc., exhibit polymorphism and some/one of the polymorphic forms of a given drug exhibit superior bio-availability and consequently show much higher activity compared to other polymorphs. Sertraline, Frentizole, Ranitidine, Sulfathiazole, Indomethacine etc. are some of the important examples of pharmaceuticals which exhibit polymorphism. Polymorphism in drugs is a topic of current interest and is evident from the host of patents being granted. To cite a few, US 5700820 discloses six polymorphic forms of Troglitazone, US 5248699 discusses about five polymorphic forms of Sertraline hydrochloride while EP 014590 describes four polymorphic forms of Frentizole. EP 490648 and EP 022527 also deal with the subject of polymorphism in drugs.
Summary of the invention
With an objective to develop novel polymorphic forms for lowering cholesterol and reducing body weight with beneficial effects in the treatment and/or prophylaxis of diseases related to increased levels of lipids, atherosclerosis, coronary artery diseases, Syndrome-X, impaired glucose tolerance, insulin resistance, insulin resistance leading to type 2 diabetes and diabetes complications thereof, for the treatment of diseases wherein insulin resistance is the pathophysiological mechanism and for the treatment of hypertension, with better efficacy, potency and lower toxicity, we focussed our research to develop new polymorphic forms effective in the treatment of the above mentioned diseases. Effort in this direction has led to polymorphic forms having the formula (I).
Another objective of the present invention is to provide polymorphic forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, their stereoisomers, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures which may have agonist activity against PPARα and/or PPARγ, and optionally inhibit HMG CoA reductase, in addition to having agonist activity against PPARα and/or PPARγ. Another objective of the present invention is to provide novel polymorphic forms of arginine salt of 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, their stereoisomers, pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures having enhanced activities, without toxic effect or with reduced toxic effect.
Yet another objective of the present invention to provide a process for the preparation of novel polymorphic forms of arginine salt of 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, their stereoisomers, pharmaceutically acceptable solvates. Still another objective of the present invention is to provide pharmaceutical compositions containing novel polymorphic forms of arginine salt of 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, their stereoisomers, solvates or their mixtures in combination with suitable carriers, solvents, diluents and other media normally employed in preparing such compositions.
In our PCT publication No. WO 99/19313 we have described novel β-aryl α-oxy substituted alkylcarboxylic acids of the general formula (a),
Figure imgf000009_0001
their pharmaceutically salts, their pharmaceutically solvated and their pharmaceutically acceptable compositions containing them. The pharmaceutical salts of the compounds of the general formula (a) includes salts of the organic bases such as guanine, arginine, guanidine, diethylamine, choline, and the like. Particularly the compounds disclosed include 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid. The current interest in the field of polymorphism in drugs prompted us to take up the investigation as to the possibility of polymorphism in such compounds particularly the arginine salt of 3- [4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid. Our observations and results form the subject matter of the present invention. We have, due to our sustained research directed towards finding out effective antidiabetic drugs, observed that arginine salt of 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, exists in different polymorphic forms possessing enhanced anti-diabetic activity. Accordingly we have, in the course of research, prepared and studied at least eleven polymorphic forms of arginine salt of 3-[4- [2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid. These polymorphs have been designated, by us, as Forms I, II, III, IV, V, VI, VII, VIII, IX, X and the mixture.
Detailed Description of the Invention
The present invention relates to an observation that arginine salt of 3-[4-[2-(phenoxazin- 10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid exhibits polymorphism, which has not been reported till date. The polymorphic Forms I, II, III, IV and V are obtained from different solvents like isopropyl alcohol, acetone, 1,4-dioxane, dimethylsulphoxide, and dimethylformamide respectively. Form VI is obtained by dissolving any form (Form I- V) in water and freeze drying. Similarly Form VII is obtained by dissolving any form (Form I-V) in methanol and quick evaporation of the solvent under reduced pressure at 40-60 °C. Form VIII is obtained by refluxing Form-I in 1,4-dioxane. Form-IX is obtained by refluxing Form- VIII in isopropyl alcohol. Form X is prepared by heating Form I to 185 °C and cooling it to room temperature. Form XI is prepared by heating Form X to 175 °C and cooling it to room temperature.
From powder X-ray diffraction studies Forms I, II, III, IV, V, VIII, IX and XI are found to be crystalline in nature. Forms VI, VII and X did not give any peaks in X- ray diffraction due to amorphous nature.
DSC of the polymorphic Form I shows melting endotherm at 181 °C. In the mixture of polymorphic Forms I and X there is an indication to one of the endotherm at 185 °C and 181 °C. Form II displays endotherms at 131 °C, 166 °C, 178 °C, 214 °C and 276 °C and exotherms at 169 °C. Form III exhibits melting endotherm 182 °C in addition to an exotherm at 168 °C. Form IV exhibits endotherms at 149 °C, 164 °C and 185 °C and an exotherm at 171 °C. Form V exhibits endotherms at 119 °C, 164 °C, 172 °C and 185 °C in addition to a melting exotherm at 173 °C. Form VI exhibits exotherm at 157 °C and endotherms at 179 °C and 183 °C. Form VII exhibits exotherm at 132 °C and endotherms at 176 °C and 184 °C. Form VIII there was a similar exotherm of Form VI at 158 °C and the melting endotherm at 178 °C, whereas in Form IX there was only one sharp melting endotherm at 176 °C. Form X displays an exotherm at 163 °JC. and melting endotherm at 184 °C. Form XI exhibits a melting endotherm at 184 °C.
All these polymorphic forms were proved to be identical in solution as evident from Nuclear Magnetic Resonance (NMR), Ultra Violet (UV) & Mass spectral data. On the other hand, solid state techniques like Differential Scanning Calorimetry (DSC), Powder X-Ray Diffractometry (XRD) and Infra Red spectroscopy (IR) revealed the difference among these forms.
Brief Description of the Figures
X-ray powder diffraction pattern has been obtained on a Rigaku D/Max 2200 model diffractometer equiped with horizontal gonimometer in Θ/2 Θ geometry. The copper K α ( λ=1.5418A) radiation was used and the sample was scanned between 3-45 degrees
2Θ.
Fig. 1 is a characteristic X-ray powder diffraction pattern of Form I.
Fig. 2 is a characteristic X-ray powder diffraction pattern of Form II.
Fig. 3 is a characteristic X-ray powder diffraction pattern of Form III. Fig. 4 is a characteristic X-ray powder diffraction pattern of Form IV.
Fig. 5 is a characteristic X-ray powder diffraction pattern of Form V.
Fig. 6 is a characteristic X-ray powder diffraction pattern of Form VI.
Fig. 7 is a characteristic X-ray powder diffraction pattern of Form VII.
Fig. 8 is a characteristic X-ray powder diffraction pattern of Form VIII. Fig. 9 is a characteristic X-ray powder diffraction pattern of Form IX.
Fig. 10 is a characteristic X-ray powder diffraction pattern of Form X. Fig. 11 is a characteristic X-ray powder diffraction pattern of Form XL Fig. 12 is a characteristic X-ray powder diffraction pattern of polymorphic form mixture.
Differential scanning calorimeter was performed on a Shimadzu DSC-50 equipped with a controller. The data was collected on to a Pentium PC using a Shimadzu TA-50 software. The samples weighed in aluminum cells were heated from room temperature to 220 °C at a heating rate of 5 °C /min. The empty aluminum cell was used as a reference. Dry nitrogen gas was purged through DSC cell continuously throughout the analysis at a flow of 30 ml/min.
Fig. 13 is a characteristic differential scanning calorimetric thermogram of Form I.
Fig. 14 is a characteristic differential scanning calorimetric thermogram of Form II.
Fig. 15 is a characteristic differential scanning calorimetric thermogram of Form III.
Fig. 16 is a characteristic differential scanning calorimetric thermogram of Form IV. Fig. 17 is a characteristic differential scanning calorimetric thermogram of Form V.
Fig. 18 is a characteristic differential scanning calorimetric thermogram of Form VI.
Fig. 19 is a characteristic differential scanning calorimetric thermogram of Form VII.
Fig. 20 is a characteristic differential scanning calorimetric thermogram of Form VIII.
Fig. 21 is a characteristic differential scanning calorimetric thermogram of Form IX. Fig. 22 is a characteristic differential scanning calorimetric thermogram of Form X.
Fig. 23 is a characteristic differential scanning calorimetric thermogram of Form XI.
Fig. 24 is a characteristic differential scanning calorimetric thermogram of polymorphic form mixture.
FT-IR Spectrum was recorded in solid state as KBr dispersion using Perkin-Elmer 1650
FT-IR Spectrophotometer.
Fig. 25 is a characteristic infrared absorption spectrum of Form I in KBr.
Fig. 26 is a characteristic infrared absorption spectrum of Form II in KBr.
Fig. 27 is a characteristic infrared absorption spectrum of Form III in KBr. Fig. 28 is a characteristic infrared absorption spectrum of Form IV in KBr.
Fig. 29 is a characteristic infrared absorption spectrum of Form V in KBr.
Fig. 30 is a characteristic infrared absorption spectrum of Form VI in KBr. Fig. 31 is a characteristic infrared absorption spectrum of Form VII in KBr. Fig. 32 is a characteristic infrared absorption spectrum of Form VIII in KBr. Fig. 33 is a characteristic infrared absorption spectrum of Form IX in KBr. Fig. 34 is a characteristic infrared absorption spectrum of Form X in KBr. Fig. 35 is a characteristic infrared absorption spectrum of Form XI in KBr. Fig. 36 is a characteristic infrared absorption spectrum of polymorphic form mixture in KBr.
According to a feature of the present invention, there is provided a novel polymorphic Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, having the formula I which is characterized by the following data
DSC: Endotherms at 181.21 °C (onset at 177.70 °C) (Fig -13)
X-ray powder diffraction (2Θ): 8.18, 12.40, 16.66, 18.80, 19.44, 22.32, 22.84,
23.10, 23.50, 24.72, 29.84, (Fig -1)
Infrared absorption bands (cm"1): 3249, 3062, 1709, 1587, 1489, 1374, 1272,
1243, 1112, 1043, 919, 737, 673, 543, (Fig -25)
According to another feature of the present invention, there is provided a novel polymorphic Form-II of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I which is characterized by the following data :
DSC: Endotherms at 131 °C, 166.24 °C and 178.96 °C (Fig -14) Exotherm at 169.73 °C
X-ray powder diffraction (2Θ): 6.78, 11.5, 12.08, 16.44, 19.34, 22.30, 22.72, 24.40, 26.66 (Fig -2)
Infrared absorption bands (cm"1): 3055, 1711, 1589, 1510, 1491, 1376, 1274, 1111, 1039, 810, 730, 543, (Fig -26) According to yet another feature of the present invention, there is provided a novel polymorphic Form-Ill of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I which is characterized by the following data :
DSC: Endotherm at 182.20 °C (onset at 171 °C) (Fig-15)
Small endotherms at 99.66 °C, 164.38 °C
Exotherm at 168.00 °C
X-ray powder diffraction (2Θ): 6.80, 12.10, 15.84, 17.02, 19.40, 22.32, 22.68, 24.38, 26.36, (Fig -3)
Infrared absorption bands (cm"1): 3061, 1710, 1588, 1510, 1491, 1379, 1273,
1110, 1040, 805, 739, and 543, (Fig -27)
According to yet another feature of the present invention, there is provided a novel polymorphic Form-IV of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I which is characterized by the following data :
DSC: Endotherms at 149.85 °C, 185.60 °C (onset at 147.78 °C) (Fig -16) Small Endotherm at 164.51 °C
Small Exotherm at 171.80 °C
X-ray powder diffraction (20): 6.78, 12.66, 15.96, 16.54, 19.34, 22.78, 24.42, 26.70, 31.70, (Fig -4)
Infrared absorption bands (cm"1): 3056, 1711, 1589, 1493, 1381, 1274, 1242, 1101, 1060, 805, 743, and 543.7, (Fig -28)
According to yet another feature of the present invention, there is provided a novel polymorphic Form-V of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I which is characterized by the following data : DSC: Endotherm at 185.95 °C, (onset at 178.09 °C) (Fig -17) Small endotherms at 119.81 °C, 164.69 °C, 172.44 °C Small exotherm at 173.82 °C
X-ray powder diffraction (20): 6.76, 12.10, 15.96, 17.00, 18.50, 19.40, 22.38, 22.44, 24.44, 26.30, (Fig -5)
Infrared absorption bands (cm"1): 3266, 3055, 1711, 1589, 1510, 1492, 1379, 1274, 1175, 1111, 1040, 918, 819, 730, 676, 544, (Fig -29)
According to yet another feature of the present invention, there is provided a novel polymorphic Form-VI of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I which is characterized by the following data :
DSC: Endotherms at 179.11 °C and 183.69 °C (onset at 157.98 °C), (Fig -18) Small endotherm at 77.80 °C
Exotherm at 157.98 °C,
X-ray powder diffraction (2Θ): No diffraction peaks due to its amorphous nature, (fig-6)
Infrared absorption bands (cm"1): 3065, 1629, 1490, 1377, 1273, 1244, 1109, 1042, 805, 740, 539, (Fig -30)
According to yet another feature of the present invention, there is provided a novel polymorphic Form- VII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I which is characterized by the following data :
DSC: Endotherms at 176.63 °C (onset at 169.06 °C) and 184.09 °C (Fig -19) Exotherm at 132.93 °C,
X-ray powder diffraction (2Θ): No diffraction peaks due to its amorphous nature, (Fig-7) Infrared absorption bands (cm"1): 3065, 1629, 1490, 1377, 1273, 1109, 1042, 740, 541, (Fig -31)
According to yet another feature of the present invention, there is provided a novel polymorphic Form- VIII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I which is characterized by the following data :
DSC: Endotherm at 178.12 °C (onset at 167.15 °C), (Fig -20) Small Endotherm at 152.72 °C
Exotherm at 158.27 °C
X-ray powder diffraction (20): 4.16, 11.02, 15.94, 19.50, 20.22, 22.22, 27.38, (Fig -8)
Infrared absorption bands (cm"1): 3151, 1629, 1490, 1378, 1272, 1244, 1104, 1041, 742, 549, (Fig -32)
According to yet another feature of the present invention, there is provided a novel polymorphic Form-IX of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I which is characterized by the following data :
DSC: Endotherm at 176.67 °C (onset at 173.36 °C), (Fig -21)
X-ray powder diffraction (2Θ): 8.20, 12.42, 16.66, 18.80, 19.44, 22.30, 23.08,
27.38, 28.48, 29.84, (Fig -9) Infrared absorption bands (cm"1): 3066, 1588, 1489, 1376, 1273, 1243, 1110,
1043, 919, 805, 737, 543, (Fig -33)
According to still another feature of the present invention, there is provided a novel polymorphic Form-X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I which is characterized by the following data :
DSC: Endotherm at 184.53 °C, (Fig -22) Exotherm at, 162.67 °C
X-ray powder diffraction (2Θ): No diffraction peaks due to its amorphous nature, (Fig -10)
Infrared absorption bands (cm"1): 3413, 1630, 1511, 1491, 1377, 1273, 1244, 1176, 1108, 741, (Fig -34)
According to yet another feature of the present invention, there is provided a novel polymoφhic Form-XI of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I which is characterized by the following data :
DSC: Endotherm at 184.40 °C (onset at 177.67 °C), (Fig -23) X-ray powder diffraction (20): 7.38, 7.56, 11.90, 12.32, 14.80, 16.40, 19.58,
20.48, 22.34, 22.90, 23.54, (Fig -11)
Infrared absoφtion bands (cm"1): 3383, 2925, 1629, 1510, 1490, 1377, 1273,
1243, 1090, 1041, 739, 539, (Fig -35)
According to yet another feature of the present invention, there is provided a novel mixture of polymoφhic Forms I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin- 10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I which is characterized by the following data :
DSC: Endotherms at 181.28 °C, 185.31 °C, (onset at 173.54 °C) (Fig -24) X-ray powder diffraction (2Θ): 8.16, 12.40, 16.64, 18.78, 19.42, 22.34, 22.80,
23.08, 29.84, (Fig -12)
Infrared absoφtion bands (cm"1): 3247, 3066, 1708, 1587, 1510, 1489, 1375, 1273, 1244, 1178, 1111, 1043, 805, 737, 673, 543, (Fig -36)
According to another feature of the present invention, there is provided a process for the preparation of novel polymoφhic Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin- 10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of the formula I, having the characteristics described earlier, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in an organic solvent,
(ii) adding L-arginine dissolved in water slowly with constant stirring to the solution obtained in step (i),
(iii) stirring the reaction mixture at a temperature of 40-80 °C for a period in the range of 18-30 h to obtain a white crystalline precipitate, (iv) filtering the white crystalline precipitate obtained in step (iii) above and
(v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-
16 h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
The temperature employed in the stirring step (iii) may be preferably 40-50 °C.
According to another feature of the present invention, there is provided an alternate process for the preparation of novel polymoφhic Form-I of L-arginine salt of (2S) 3-[4- [2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of the formula I, having the characteristics described earlier, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in an organic solvent,
(ii) adding L-arginine dissolved in water slowly with constant stirring to the solution obtained in step (i),
(iii) stirring the reaction mixture at room temperature for a period in the range of 90-
100 h to obtain a white crystalline precipitate,
(iv) filtering the white crystalline precipitate obtained in step (iii) above and
(v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid. According to another feature of the present invention, there is provided a process for the preparation of novel polymoφhic Form-II of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of the formula I, having the characteristics described earlier, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in acetone, (ii) adding L-arginine dissolved in water slowly with constant stirring to the solution obtained in step (i),
(iii) stirring the reaction mixture at room temperature for a period in the range of 18-
30 h to obtain a white crystalline precipitate
(iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-
16 h to yield Form-II of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
According to yet another feature of the present invention, there is provided a process for the preparation of novel polymoφhic Form-Ill of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid of the formula I, having the characteristics described earlier, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in 1 ,4-dioxane,
(ii) adding L-arginine dissolved in water slowly with constant stirring to the solution obtained in step (i),
(iii) stirring the reaction mixture at room temperature for a period in the range of 18-
30 h to obtain a white crystalline precipitate (iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield Form-Ill of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
According to yet another feature of the present invention, there is provided a process for the preparation of novel polymoφhic Form-IV of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid of the formula I, having the characteristics described earlier, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in dimethyl sulfoxide, (ii) adding L-arginine dissolved in water slowly with constant stirring to the solution obtained in step (i), (iii) stirring the reaction mixture at room temperature for a period in the range of 18- 30 h to obtain a white crystalline precipitate
(iv) filtering the white crystalline precipitate obtained in step (iii) above and
(v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-
16 h to yield Form-IV of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
According to another feature of the present invention, there is provided a process for the preparation of novel polymoφhic Form-V of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid of the formula I, having the characteristics described earlier, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in dimethyl formamide, (ii) adding L-arginine dissolved in water slowly with constant stirring in the solution obtained in step (i), (iii) stirring the reaction mixture at room temperature for a period in the range of 18- 30 h to obtain a white crystalline precipitate, (iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield Form-V of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
According to another feature of the present invention, there is provided a process for the preparation of novel polymoφhic Form-VI of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid of the formula I, having the characteristics described earlier, which comprises :
(i) dissolving any of the polymoφhic Forms I-V of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid in water and (ii) freeze drying the resulting solution to yield an amoφhous white powder of Form-VI of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid.
According to another feature of the present invention, there is provided a process for the preparation of novel polymoφhic Form-VII of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid of the formula I, having the characteristics described earlier, which comprises :
(i) dissolving any of the polymoφhic Forms I-V of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid in methanol and (ii) evaporating the resulting solution under vacuum to obtain an amoφhous white powder of Form-VII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
According to another feature of the present invention, there is provided a process for the preparation of novel polymoφhic Form-VIII of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of the formula I, having the characteristics described earlier, which comprises : (i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in an organic solvent, (ii) adding L-arginine dissolved in water slowly with constant stirring in the solution obtained in step (i), (iii) stirring the reaction mixture at a temperature of 40-80 °C for a period in the range of 18-30 h to obtain a white crystalline precipitate, (iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
(vi) refluxing the Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, obtained above in step (v) in 1,4-dioxane for a period in the range of 8-16 h and (vii) filtering and drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-16 h to yield Form- VIII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
According to another feature of the present invention, there is provided a process for the preparation of novel polymoφhic Form-IX of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of the formula I, having the characteristics described earlier, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in an organic solvent, (ii) adding L-arginine dissolved in water slowly with constant stirring in the solution obtained in step (i),
(iii) stirring the reaction mixture at a temperature of 40-80 °C for a period in the range of 18-30 h to obtain a white crystalline precipitate, (iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-
16 h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl] -2-ethoxypropanoic acid,
(vi) refluxing the Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, obtained above in step (v) in 1 ,4-dioxane for a period in the range of 8-16 h,
(vii) filtering and drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-16 h to yield Form- VIII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, (viii) refluxing the Form- VIII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, obtained in step (vii) above in isopropyl alcohol for a period in the range of 8-16 h and
(ix) filtering and drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-16 h to yield Form-IX of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
According to another feature of the present invention, there is provided a process for the preparation of novel polymoφhic Form-X of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of the formula I, having the characteristics described earlier, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in an organic solvent,
(ii) adding L-arginine dissolved in water slowly with constant stirring to the solution obtained in step (i),
(iii) stirring the reaction mixture at a temperature of 40-80 °C for a period in the range of 18-30 h to obtain a white crystalline precipitate,
(iv) filtering the white crystalline precipitate obtained in step (iii) above and
(v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid and (vi) heating the polymoφhic Form-I obtained in step (v) to 185 °C and cooling it to room temperature to yeild Form-X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
According to another feature of the present invention, there is provided a process for the preparation of novel polymoφhic Form-XI of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of the formula I, having the characteristics described earlier, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in an organic solvent, (ii) adding L-arginine dissolved in water slowly with constant stirring to the solution obtained in step (i), (iii) stirring the reaction mixture at a temperature of 40-80 °C for a period in the range of 18-30 h to obtain a white crystalline precipitate,
(iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, (vi) heating the polymoφhic Form-I obtained in step (v) to 185 °C and cooling it to room temperature to yeild Form-X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid and
(vii) heating the polymoφhic Form-X obtained in step (vi) to 175 °C and cooling it to room temperature to yield Form-XI of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
According to another feature of the present invention, there is provided a process for the preparation of novel mixture of polymoφhic Form of I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of the formula I, described earlier, which comprises : (i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in an organic solvent, (ii) adding L-arginine dissolved in water slowly with constant stirring in the solution obtained in step (i), (iii) stirring the reaction mixture at room temperature for a period in the range of 18- 30 h to separate white crystalline powder,
(iv) filtering the white crystalline powder obtained in step (iii) and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield mixture of polymoφhic Form of I and X of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
According to another feature of the present invention, there is provided an alternate process for the preparation of novel polymoφhic Form-I of L-arginine salt of (2S) 3-[4- [2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of the formula I, having the characteristics described earlier, which comprises :
(i) suspending any of the polymoφhic Form II to XI or the mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid in isopropyl alcohol and stirring in dark conditions at room temperature for a period of 35-50 h,
(ii) filtering and washing with isopropyl alcohol and
(iii) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield polymoφhic Form of I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl] -2-ethoxypropanoic acid,
The organic solvents are selected from acetonitrile, ethanol, methanol and, isopropanol.
The present invention also envisages a pharmaceutical composition comprising a polymoφhic Forms I to XI of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of the formula (I) or the mixture of polymoφhic Form of I and X and a pharmaceutically acceptable carrier . The present invention also envisages a pharmaceutical composition comprising a mixture of any of polymoφhic Forms I to XI of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of the formula (I) and a pharmaceutically acceptable carrier .
The pharmaceutical composition may be in the forms normally employed, such as tablets, capsules, powders, syrups, solutions, suspensions and the like, may contain flavourants, sweeteners etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions. Such compositions typically contain from 1 to 25 %, preferably 1 to 15 % by weight of active ingredient, the remainder of the composition being pharmaceutically acceptable carriers, diluents or solvents.
The polymoφhic forms of the formula (I) as defined above are clinically administered to mammals, including man, via either oral, nasal, pulmonary, transdermal or parenteral, rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment. Administration by the oral route is preferred, being more convenient and avoiding the possible pain and irritation of injection. However, in circumstances where the patient cannot swallow the medication, or absoφtion following oral administration is impaired, as by disease or other abnormality, it is essential that the drug be administered parenterally. By either route, the dosage is in the range of about 0.01 to about 100 mg / kg body weight of the subject per day or preferably about 0.01 to about 30 mg / kg body weight per day administered singly or as a divided dose. However, the optimum dosage for the individual subject being treated will be determined by the person responsible for treatment, generally smaller doses being administered initially and thereafter increments made to determine the most suitable dosage.
Suitable pharmaceutically acceptable carriers include solid fillers or diluents and sterile aqueous or organic solutions. The active ingredient will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above. Thus, for oral administration, the polymoφhic form can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like. The pharmaceutical compositions, may, if desired, contain additional components such as flavourants, sweeteners, excipients and the like. For parenteral administration, the polymoφhic form can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically- acceptable acid addition salts or salts with base of the compounds. Aqueous solutions with the active ingredient dissolved in polyhydroxylated castor oil may also be used for injectable solutions. The injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.
For nasal administration, the preparation may contain the polymoφhic forms of the present invention dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, such as propylene glycol, surfactants, absoφtion enhancers such as lecithin (phosphatidylcholine) or cyclodextrin or preservatives such as parabenes.
Tablets, dragees or capsules having talc and / or a carbohydrate carried binder or the like are particularly suitable for any oral application. Preferably, carriers for tablets, dragees or capsules include lactose, corn starch and / or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.
A typical tablet production method is exemplified below : Tablet Production Example :
a) 1) Active ingredient 30 g 2) Lactose 95 g
3) Corn starch 30 g
4) Carboxymethyl cellulose 44 g 5) Magnesium stearate
200 g for 1000 tablets
The ingredients 1 to 3 are uniformly blended with water and granulated after drying under reduced pressure. The ingredient 4 and 5 are mixed well with the granules and compressed by a tabletting machine to prepare 1000 tablets each containing 30 mg of active ingredient.
1 ) Active ingredient 30 g
2) Calcium phosphate 90 g
3) Lactose 40 g
4) Corn starch 35 g
5) Polyvinyl pyrrolidone 3.5 g
6) Magnesium stearate 1.5 g
200 g for 1000 tablets
The ingredients 1-4 are uniformly moistened with an aqueous solution of 5 and granulated after drying under reduced pressure. Ingredient 6 is added and granules are compressed by a tabletting machine to prepare 1000 tablets containing 30 mg of ingredient 1.
Examples :
Synthesis of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, is described in our WO publication No. WO 99/19313 and copending PCT application No. PCT/IB99/00683.
The present invention is described in detail in the examples given below which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention. Examples 1-4 illustrates the process for the preparation of the polymorphic Form-1 of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid,
Example-1 :
To a solution of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1 g) in ethanol (25 ml) was added L-arginine dissolved in water (1.2 ml) slowly with constant stirring. The reaction mixture was stirred at 40-50 °C for 24h. The white crystalline precipitate formed was separated and dried under vacuum at 40-45 °C for 4h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid (1.15 g) which has the characteristics given earlier.
Example-2
To a solution of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1 g) in isopropyl alcohol (25 ml) was added L-arginine dissolved in water (1.2 ml) slowly with constant stirring. The reaction mixture was stirred at 40-50 °C for 24h. The white crystalline precipitate formed was separated and dried under vacuum at 40-45 °C for 4h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1.27 g) which has the characteristics given earlier.
Example -3
To a solution of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1 g) in acetonitrile (25 ml) was added L-arginine dissolved in water (1.2 ml) slowly with constant stirring. The reaction mixture was stirred at 40-50 °C for 24h. The white crystalline precipitate formed was separated and dried under vacuum at 40-45 °C for 4h to yield Form-I L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid (1.24 g) which has the characteristics given earlier. Example-4 :
To a solution of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1 g) in methanol (15 ml) was added L-arginine dissolved in water (1.2 ml) slowly with constant stirring. The reaction mixture was stirred at 40-50 °C for 24h. The white crystalline precipitate formed was separated and dried under vacuum at 40-45 °C for 4h to yield Form-I L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid (1.05 g) which has the characteristics given earlier.
Example-5 :
To a solution of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1 g) in isopropyl alcohol (25 ml) was added L-arginine dissolved in water (1.2 ml) slowly with constant stirring. The reaction mixture was stirred at room temperature for 90-100 h. The white crystalline precipitate formed was separated and dried under vacuum at 40-45 °C for 4h to yield Form-I L-arginine salt of (2S) 3-[4-[2-(phenoxazin- 10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1.05 g) which has the characteristics given earlier.
Example 6 : Process for the preparation of the polymorphic Form-II of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
To a solution of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1 g) in acetone (25 ml) was added L-arginine dissolved in water (1.2 ml) slowly with constant stirring. The reaction mixture was stirred at room temperature for 24h. The white crystalline precipitate formed was separated and dried under vacuum at 40-45 °C for 4h to yield Form-II of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1.29 g) which has the characteristics given earlier. Example 7 : Process for the preparation of the polymorphic Form-Ill of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
To a solution of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1 g) in 1,4-dioxane (25 ml) was added L-arginine dissolved in water (1.2 ml) slowly with constant stirring. The reaction mixture was stirred at room temperature for 24h. The white crystalline precipitate formed was separated and dried under vacuum at 40-45 °C for 4h to yield Form-Ill of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1.25 g) which has the characteristics given earlier.
Example 8 : Process for the preparation of the polymorphic Form-IV of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
To a solution of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1 g) in DMSO (20 ml) was added L-arginine dissolved in water (1.2 ml) slowly with constant stirring. The reaction mixture was stirred at room temperature for 24h. The white crystalline precipitate formed was separated and dried under vacuum at 40-45 °C for 4h to yield Form-Ill of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1.3 g) which has the characteristics given earlier.
Example 9 : Process for the preparation of the polymorphic Form-V of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
To a solution of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid
(1 g) in DMF (25 ml) was added L-arginine dissolved in water (1.2 ml) slowly with constant stirring. The reaction mixture was stirred at room temperature for 24h. The white crystalline precipitate formed was separated and dried under vacuum at 40-45 °C for 4h to yield Form-V of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1.17 g) which has the characteristics given earlier.
Example 10 : Process for the preparation of the polymorphic Form-VI of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
Polymoφhic Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1 g), obtained by the process described in Example-2 above was dissolved in water (10 ml) and freeze dried to yield Form-VI of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, as an amoφhous white powder (0.95 g) which has the characteristics given earlier.
Example 11 : Process for the preparation of the polymorphic Form-VII of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
Polymoφhic Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1 g), obtained by the process described in Example-3 above was dissolved in methanol (25 ml) and evaporated under vacuum to yield Form-VII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, as an amoφhous white powder (0.9 g) which has the characteristics given earlier.
Example 12 : Process for the preparation of the polymorphic form- VIII of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, Polymoφhic Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1 g), obtained by the process described in Example-2 above was refluxed in 1,4-dioxane (10 ml), filtered and dried under vacuum to yield Form- VIII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]- 2-ethoxypropanoic acid which has the characteristics given earlier.
Example 13 : Process for the preparation of the polymorphic Form-IX of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
Polymoφhic Form- VIII L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1 g), obtained by the process described in Example- 12 was refluxed in isopropanol (10 ml), filtered and dried under vacuum to yield Form-IX of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid which has the characteristics given earlier.
Example 14 : Process for the preparation of the polymorphic Form-X of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
Polymoφhic Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid obtained by any of the process described in Examples- 1-5 was heated to 185 °C and cooled it to room temperature to yield Form-X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid which has the characteristics given earlier.
Example 15 : Process for the preparation of the polymorphic Form-XI of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, Polymoφhic Form-X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid obtained by the process described in Example 14 was heated to 175 °C and cooled it to room temperature to yield Form-XI of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid which has the characteristics given earlier.
Example 16 : Process for the preparation of mixture of polymorphic Forms I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid,
To a solution of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1 g) in isopropyl alcohol (25 ml) was added L-arginine dissolved in water (1.2 ml) slowly with constant stirring. The reaction mixture was stirred at room temperature for 24h. The white crystalline powder formed was separated and dried under vacuum at 40- 45 °C for 4h to yield a mixture of polymoφhic Forms I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1.05 g).
Example 17 : Process for the preparation of polymorphic Form I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
A mixture of polymoφhic Forms I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin- 10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid (1.0 g) is suspended in isopropyl alcohol (10 ml) the reaction flask was covered with carbon paper and stirred at room temperature for a period of 35-50 h. The reaction mixture was filtered, washed with little isopropyl alcohol and dried under vacuum at 40-45 °C for 4h to yield polymoφhic Form I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid (0.97 g). ADVANTAGES OF THE INVENTION :
• The polymoφhic Forms of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, are more active / bio-available and are therefore very useful for the treatment or prophylaxis.
• Ease in formulation containing these forms resulting in higher activity / bioavailability, in terms of lowering plasma blood sugar and plasma triglycerides.

Claims

We claim
1. A polymoφhic Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I,
Figure imgf000036_0001
which is characterized by the data described hereunder :
DSC: Endotherms at 181.21 °C (onset at 177.70 °C)
X-ray powder diffraction (2Θ): 8.18, 12.40, 16.66, 18.80, 19.44, 22.32, 22.84, 23.10, 23.50, 24.72, 29.84,
Infrared absoφtion bands (cm"1): 3249, 3062, 1709, 1587, 1489, 1374, 1272, 1243, 1112, 1043, 919, 737, 673, 543.
2. A polymoφhic Form-II of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I,
Figure imgf000036_0002
which is characterized by the data described hereunder :
DSC: Endotherms at 131 °C, 166.24 °C and 178.96 °C
Exotherm at 169.73 °C
X-ray powder diffraction (2Θ): 6.78, 11.5, 12.08, 16.44, 19.34, 22.30, 22.72,
24.40, 26.66 Infrared absoφtion bands (cm"1): 3055, 1711, 1589, 1510, 1491, 1376, 1274,
1111, 1039, 810, 730, 543.
3. A polymoφhic Form-Ill of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I,
Figure imgf000037_0001
which is characterized by the data described hereunder : DSC: Exotherm at 168.00 °C Endotherm at 182.20 °C (onset at 171 °C), Small endotherms at 99.66 °C, 164.38 °C
X-ray powder diffraction (20): 6.80, 12.10, 15.84, 17.02, 19.40, 22.32, 22.68, 24.38, 26.36,
Infrared absoφtion bands (cm"1): 3061, 1710, 1588, 1510, 1491, 1379, 1273, 1110, 1040, 805, 739, and 543.
4. A polymoφhic Form-IV of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, -having the formula I,
Figure imgf000037_0002
which is characterized by the data described hereunder : DSC: Small Exotherm at 171.80 °C
Endotherms at 149.85 °C, 185.60 °C (onset at 147.78 °C) Small Endotherm at 164.51 °C
X-ray powder diffraction (2Θ): 6.78, 12.66, 15.96, 16.54, 19.34, 22.78, 24.42, 26.70, 31.70, Infrared absoφtion bands (cm"1): 3056, 1711, 1589, 1493, 1381, 1274, 1242,
1101, 1060, 805, 743, and 543.7.
5. A polymoφhic Form-V of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I,
Figure imgf000038_0001
which is characterized by the data described hereunder : DSC: Small exotherm at 173.82 °C Endotherm at 185.95 °C, (onset at 178.09 °C) Small endotherms at 119.81 °C, 164.69 °C, 172.44 °C
X-ray powder diffraction (20): 6.76, 12.10, 15.96, 17.00, 18.50, 19.40, 22.38, 22.44, 24.44, 26.30,
Infrared absoφtion bands (cm"1): 3266, 3055, 1711, 1589, 1510, 1492, 1379, 1274, 1175, 1111, 1040, 918, 819, 730, 676, 544.
6. A polymoφhic Form-VI of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I,
Figure imgf000038_0002
which is characterized by the data described hereunder : DSC: Exotherm at 157.98 °C,
Endotherms at 179.11 °C and 183.69 °C (onset at 157.98 °C), Small endotherm at 77.80 °C
X-ray powder diffraction (20): No diffraction peaks due to its amoφhous nature, Infrared absoφtion bands (cm"1): 3065, 1629, 1490, 1377, 1273, 1244, 1109, 1042, 805, 740, 539.
7. A polymoφhic Form-VII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I,
Figure imgf000039_0001
which is characterized by the data described hereunder :
DSC: Exotherm at 132.93 °C,
Endotherms at 176.63 °C (onset at 169.06 °C) and 184.09 °C
X-ray powder diffraction (20): No diffraction peaks due to its amoφhous nature,
Infrared absoφtion bands (cm"1): 3065, 1629, 1490, 1377, 1273, 1109, 1042,
740, 541.
8. A polymoφhic Form- VIII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I,
Figure imgf000039_0002
which is characterized by the data described hereunder : DSC: Exotherm at 158.27 °C Endotherm at 178.12 °C (onset at 167.15 °C), Small Endotherm at 152.72 °C
X-ray powder diffraction (2Θ): 4.16, 11.02, 15.94, 19.50, 20.22, 22.22, 27.38, Infrared absoφtion bands (cm"1): 3151, 1629, 1490, 1378, 1272, 1244, 1104, 1041, 742, 549.
9. A polymoφhic Form-IX of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I,
Figure imgf000039_0003
which is characterized by the data described hereunder :
DSC: Endotherm at 176.67 °C (onset at 173.36 °C), (Fig -21)
X-ray powder diffraction (29): 8.20, 12.42, 16.66, 18.80, 19.44, 22.30, 23.08,
27.38, 28.48, 29.84, (Fig -9)
Infrared absoφtion bands (cm"1): 3066, 1588, 1489, 1376, 1273, 1243, 1110,
1043, 919, 805, 737, 543, (Fig -33)
10. A polymoφhic Form-X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I,
Figure imgf000040_0001
which is characterized by the data described hereunder : DSC: Endotherm at 184.53 °C,) Exotherm at, 162.67 °C
X-ray powder diffraction (20): No diffraction peaks due to its amoφhous nature, Infrared absoφtion bands (cm"1): 3413, 1630, 1511, 1491, 1377, 1273, 1244,
1176, 1108, 741.
11. A polymoφhic Form-XI of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I,
Figure imgf000040_0002
which is characterized by the data described hereunder :
DSC: Endotherm at 184.40 °C (onset at 177.67 °C),
X-ray powder diffraction (29): 7.38, 7.56, 11.90, 12.32, 14.80, 16.40, 19.58,
20.48, 22.34, 22.90, 23.54, Infrared absoφtion bands (cm"1): 3383, 2925, 1629, 1510, 1490, 1377, 1273, 1243, 1090, 1041, 739, 539.
12. A mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I,
Figure imgf000041_0001
which is characterized by the following data :
DSC: Endotherms at 181.28 °C, 185.31 °C, (onset at 173.54 °C) X-ray powder diffraction (29): 8.16, 12.40, 16.64, 18.78, 19.42, 22.34, 22.80,
23.08, 29.84,
Infrared absoφtion bands (cm"1): 3247, 3066, 1708, 1587, 1510, 1489, 1375, 1273, 1244, 1178, 1111, 1043, 805, 737, 673, 543.
13. A pharmaceutical composition comprising any one of polymoφhic Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, having the formula I
Figure imgf000041_0002
and a pharmaceutically acceptable carrier, diluent, excipient or solvate.
14. A process for the preparation of the polymoφhic Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the characteristics defined in claim 1 , which comprises : (i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in an organic solvent, (ii) adding L-arginine dissolved in water slowly with constant stirring to the solution obtained in step (i), (iii) stirring the reaction mixture at a temperature of 40-80 °C for a period in the range of 18-30 h to obtain a white crystalline precipitate, (iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-
16 h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
15. A process for the preparation of the polymoφhic Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the characteristics defined in claim 1, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in an organic solvent, (ii) adding L-arginine dissolved in water slowly with constant stirring to the solution obtained in step (i), (iii) stirring the reaction mixture at room temperature for a period in the range of 90- 100 h to obtain a white crystalline precipitate, (iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
16. A process for the preparation of the polymoφhic Form-II of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the characteristics defined in claim 2, which comprises : (i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in acetone, (ii) adding L-arginine dissolved in water slowly with constant stirring to the solution obtained in step (i), (iii) stirring the reaction mixture at room temperature for a period in the range of 18-
30 h to obtain a white crystalline precipitate (iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-
16 h to yield Form-II of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
17. A process for the preparation of the polymoφhic Form-Ill of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the characteristics defined in claim 3, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in 1,4-dioxane, (ii) adding L-arginine dissolved in water slowly with constant stirring to the solution obtained in step (i), (iii) stirring the reaction mixture at room temperature for a period in the range of 18- 30 h to obtain a white crystalline precipitate (iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield Form-Ill of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
18. A process for the preparation of the polymoφhic Form-IV of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the characteristics defined in claim 4, which comprises : (i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in dimethyl sulfoxide, (ii) adding L-arginine dissolved in water slowly with constant stirring to the solution obtained in step (i), (iii) stirring the reaction mixture at room temperature for a period in the range of 18-
30 h to obtain a white crystalline precipitate (iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-
16 h to yield Form-IV of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
19. A process for the preparation of the polymoφhic Form-V of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the characteristics defined in claim 5, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in dimethyl formamide, (ii) adding L-arginine dissolved in water slowly with constant stirring in the solution obtained in step (i), (iii) stirring the reaction mixture at room temperature for a period in the range of 18- 30 h to obtain a white crystalline precipitate, (iv) filtering the white crystalline precipitate obtained in step (iii) above and (vi) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield Form-V of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
20. A process for the preparation of the polymoφhic Form-VI of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the characteristics defined in claim 6, which comprises : (i) dissolving any of the polymoφhic Forms I-V of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, in water and
(ii) freeze drying the resulting solution to yield an amoφhous white powder of Form-VI of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid.
21. A process for the preparation of the polymoφhic Form-VII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the characteristics defined in claim 7, which comprises :
(i) dissolving any of the polymoφhic Forms I-V of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, in methanol and
(ii) evaporating the resulting solution under vacuum to obtain an amoφhous white powder of Form-VII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
22. A process for the preparation of the polymoφhic Form- VIII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the characteristics defined in claim 8, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in an organic solvent, (ii) adding L-arginine dissolved in water slowly with constant stirring in the solution obtained in step (i), (iii) stirring the reaction mixture at a temperature of 40-80 °C for a period in the range of 18-30 h to obtain a white crystalline precipitate, (iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, (vi) refluxing the Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, obtained above in step (v) in 1,4- dioxane for a period in the range of 8-16 h and
(vii) filtering and drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-16 h to yield Form- VIII of L-arginine salt of (2S) 3-[4-[2-
(phenoxazin- 10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
23. A process for the preparation of the polymoφhic Form-IX of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the characteristics defined in claim 9, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in an organic solvent, (ii) adding L-arginine dissolved in water slowly with constant stirring in the solution obtained in step (i),
(iii) stirring the reaction mixture at a temperature of 40-80 °C for a period in the range of 18-30 h to obtain a white crystalline precipitate, (iv) filtering the white crystalline precipitate obtained in step (iii) above and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, (vi) refluxing the Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, obtained above in step (v) in 1,4- dioxane for a period in the range of 8-16 h, (vii) filtering and drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-16 h to yield Form- VIII of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, (viii) refluxing the Form- VIII of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, obtained in step (vii) above in isopropyl alcohol for a period in the range of 8-16 h and (viii) filtering and drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-16 h to yield Form-IX of L-arginine salt of (2S) 3-[4-[2- (phenoxazin- 10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
24. A process for the preparation of the polymoφhic Form-X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the characteristics defined in claim 10, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in an organic solvent,
(ii) adding L-arginine dissolved in water slowly with constant stirring to the solution obtained in step (i), (iii) stirring the reaction mixture at a temperature of 40-80 °C for a period in the range of 18-30 h to obtain a white crystalline precipitate, (iv) filtering the white crystalline precipitate obtained in step (iii) above and
(v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4-
16 h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid and
(vi) heating the polymoφhic Form-I obtained in step (v) at 185 °C and cooling it to room temperature to yeild Form-X of L-arginine salt of (2S) 3-[4-[2-
(phenoxazin- 10-yl)ethoxy]phenyl] -2-ethoxypropanoic acid.
25. A process for the preparation of the polymoφhic Form-XI of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the characteristics defined in claim 11 , which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in an organic solvent, (ii) adding L-arginine dissolved in water slowly with constant stirring to the solution obtained in step (i), (iii) stirring the reaction mixture at a temperature of 40-80 °C for a period in the range of 18-30 h to obtain a white crystalline precipitate,
(iv) filtering the white crystalline precipitate obtained in step (iii) above and
(v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield Form-I of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid,
(vi) heating the polymoφhic Form-I obtained in step (v) to 185 °C and cooling it to room temperature to yeild Form-X of L-arginine salt of (2S) 3-[4-[2- (phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid and (vii) heating the polymoφhic Form-X obtained in step (vi) to 175 °C and cooling it to room temperature to yield Form-XI of L-arginine salt of (2S) 3-[4-[2- (phenoxazin- 10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
26. A process for the preparation of the mixture of polymoφhic Form I and X of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, having the characteristics defined in claim 11, which comprises :
(i) synthesizing (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, employing known methods and dissolving in an organic solvent
(ii) adding L-arginine dissolved in water slowly with constant stirring in the solution obtained in step (i), (iii) stirring the reaction mixture at room temperature for a period in the range of 18- 30 h to separate white crystalline powder,
(iv) filtering the white crystalline powder obtained in step (iii) and (v) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3- [4-[2-(phenoxazin- 10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
27. A process for the preparation of polymoφhic Form I of L-arginine salt of (2S) 3- [4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the characteristics defined in claim 1 , which comprises :
(i) suspending any of the polymoφhic Form II to XI or the mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid in isopropyl alcohol and stirring in dark conditions at room temperature for a period of 35-50 h, (ii) filtering and washing with isopoφyl alcohol and (iii) drying under vacuum at a temperature of 40-45 °C for a period in the range of 4- 16 h to yield polymoφhic Form of I of L-arginine salt of (2S) 3-[4-[2- (phenoxazin- 10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid.
28. A pharmaceutical composition comprising a mixture of any of polymoφhic Forms I to XI of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, of the formula (I) and a pharmaceutically acceptable carrier, diluent, excipient or solvate.
29. A process as claimed in claims 14 and 22 to 26, wherein the organic solvents are selected from acetonitrile, ethanol, methanol, 1,4-dioxane, and isopropanol.
30. A pharmaceutical composition as claimed in claim 13, in the form of a tablet, capsule, powder, syrup, solution or suspension.
31. A method of preventing or treating hyperlipemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering a polymoφhic Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 to a patient in need thereof.
32. A method according to claim 31 , wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma and cancer.
33. A method according to claim 31 for the treatment and / or prophylaxis of disorders related to Syndrome X, which comprises administering an agonist of PPARα and / or PPARγ of formula (I).
34. A method of reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL and free fatty acids in the plasma comprising administering a polymoφhic Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13 and 30.
35. A method of preventing or treating hyperlipemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering a polymoφhic Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 in combination / concomittant with HMG CoA reductase inhibitors or fibrates or nicotinic acid or cholestyramine or colestipol or probucol which may be administered together or within such a period as to act synergistically together to a patient in need thereof.
36. A method according to claim 35, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma and cancer.
37. A method according to claim 35 for the treatment and / or prophylaxis of disorders related to Syndrome X, which comprises administering a polymoφhic
Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, having the formula I as defined in claims 1-12 in combination with HMG CoA reductase inhibitors or fibrates or nicotinic acid or cholestyramine or colestipol or probucol which may be administered together or within such a period as to act synergistically together.
38. A method of reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL and free fatty acids in the plasma, which comprises administering a polymoφhic Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 in combination / concomittant with HMG CoA reductase inhibitors or fibrates or nicotinic acid or cholestyramine or colestipol or probucol which may be administered together or within such a period as to act synergistically together to a patient in need thereof.
39. A method according to claim 35 for the treatment and / or prophylaxis of disorders related to Syndrome X, which comprises administering to a patient in need thereof an agonist of PPARα and / or PPARγ of formula (I) as claimed in claims 1-12 or a pharmaceutical composition according to claim 13 or 30 and HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol or their combination within such a period as to act synergistically.
40. Use of a polymoφhic Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 for preventing or treating hyperlipidemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism.
41. Use of a polymoφhic Form according to claim 40, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to
Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.
42. Use of a polymoφhic Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 for reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL and free fatty acids in the plasma.
43. Use of a polymoφhic Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 in combination/concomittant with HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol which may be administered together or within such a period as to act synergistically together for preventing or treating hyperlipidemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism to a patient in need thereof.
44. Use of a polymoφhic Form according to claim 43, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to
Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.
45. Use of a polymoφhic Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 in combination/concomittant with HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol for reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma.
46. Use of a polymoφhic Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 for preparing a medicament for preventing or treating hyperlipidemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism.
47. Use of a polymoφhic form according to claim 37, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to Syndrome X such as hyper-tension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.
48. Use of a polymoφhic Form selected from Form I to XI or a mixture of polymorphic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 for preparing a medicament for reducing plasma glucose, triglycerides, total cholesterol, LDL, NLDL and free fatty acids in the plasma.
49. Use of a polymoφhic Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 for preparing a medicament in combination/concomittant with HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol for preventing or treating hyperlipemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism.
50. Use of a polymoφhic form according to claim 49, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to
Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.
51. Use of a polymorphic Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 for preparing a medicament in combination/concomittant with HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol for reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma.
52. A medicine for preventing or treating hyperlipidemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering an effective amount of a polymorphic Form selected from Form I to XI or a mixture of polymoφhic
Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 .
53. A medicine according to claim 52, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.
54. A medicine for reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL and free fatty acids in the plasma comprising an effective amount of a polymoφhic Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 .
55. A medicine for preventing or treating hyperlipidemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising a polymoφhic Form selected from Form I to XI or a mixture of polymoφhic Form I and X of L-arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 and HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol.
56. A medicine according to claim 55, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.
57. A medicine for reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL and free fatty acids in the plasma, which comprises a polymorphic Form selected from Form I to XI or a mixture of polymorphic Form I and X of L- arginine salt of (2S) 3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2- ethoxypropanoic acid, having the formula I as defined in claims 1-12 or a pharmaceutical composition as claimed in claims 13, 28 and 30 and HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol.
PCT/IB2000/000470 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them WO2000063192A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2000612284A JP2003508348A (en) 1999-04-16 2000-04-17 Novel polymorphic forms of antidiabetic agents: methods for their preparation and pharmaceutical compositions containing them
AU38313/00A AU3831300A (en) 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
MXPA01010472A MXPA01010472A (en) 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them.
IL14595800A IL145958A0 (en) 1999-04-16 2000-04-17 Polymorphic form of arginine salt of (2s)-3-[4-[2-phenoxazin-10-yl)ethoxy] phenyl]2-ethoxypropanoic acid, processes for the preparation thereof and pharmaceutical compositions containing the same
CA002370401A CA2370401A1 (en) 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
EEP200100529A EE200100529A (en) 1999-04-16 2000-04-17 Novel Polymorphic Forms of the Antidiabetic Agent: Method of Preparation and Pharmaceutical Compositions Containing Them
EP00917222A EP1171430A1 (en) 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
BR0010683-6A BR0010683A (en) 1999-04-16 2000-04-17 Polymorphic forms of an antidiabetic agent: process for its preparation and pharmaceutical compositions containing the same
HR20010748A HRP20010748A2 (en) 1999-04-16 2001-10-15 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
NO20015016A NO20015016L (en) 1999-04-16 2001-10-15 New polymorphic forms of an antidiabetic agent; process for their preparation and pharmaceutical compositions containing them
BG106022A BG106022A (en) 1999-04-16 2001-10-16 Novel polymorphic forms of an antidiabetic agent, process for their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IBPCT/IB99/00681 1999-04-16
PCT/IB1999/000681 WO2000063191A1 (en) 1999-04-16 1999-04-16 Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
IN436/MAS/99 1999-04-19
IN436MA1999 1999-04-19

Publications (1)

Publication Number Publication Date
WO2000063192A1 true WO2000063192A1 (en) 2000-10-26

Family

ID=26318745

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000470 WO2000063192A1 (en) 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them

Country Status (17)

Country Link
EP (1) EP1171430A1 (en)
CN (1) CN1351597A (en)
AU (1) AU3831300A (en)
BG (1) BG106022A (en)
BR (1) BR0010683A (en)
CA (1) CA2370401A1 (en)
CZ (1) CZ20013711A3 (en)
EE (1) EE200100529A (en)
HR (1) HRP20010748A2 (en)
HU (1) HUP0200758A3 (en)
IL (1) IL145958A0 (en)
MX (1) MXPA01010472A (en)
NO (1) NO20015016L (en)
PL (1) PL351492A1 (en)
RU (1) RU2001130883A (en)
TR (1) TR200103851T2 (en)
WO (1) WO2000063192A1 (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062772A1 (en) * 2001-02-05 2002-08-15 Dr. Reddy's Research Foundation Salts of 3-4(4-(2-phenoxazin- or phenothiazin-10-yl)alkoxy)phenyl)-2-alkoxypropanoic acid derivatives with ppar activity for the treatment of hyperlipimedia and type ii diabetes
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
WO2004101505A1 (en) 2003-05-14 2004-11-25 Novo Nordisk A/S Novel compounds for treatment of obesity
WO2005030797A2 (en) 2003-09-30 2005-04-07 Novo Nordisk A/S Melanocortin receptor agonists
JP2005529120A (en) * 2002-04-19 2005-09-29 ファエス・ファルマ・ソシエダッド・アノニマ 4- [2- [1- (2-Ethoxyethyl) -1H-benzimidazol-2-yl] -1-piperidinyl] ethyl] -α, α-dimethylbenzenoacetic acid polymorph
WO2005105785A2 (en) 2004-05-04 2005-11-10 Novo Nordisk A/S Indole derivatives for treatment of obesity
EP1634605A2 (en) 2000-03-08 2006-03-15 Novo Nordisk A/S Treatment of dyslipidemia in a patient having type 2 diabetes
WO2006053906A1 (en) 2004-11-22 2006-05-26 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
WO2006058923A1 (en) 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
WO2007006814A1 (en) 2005-07-14 2007-01-18 Novo Nordisk A/S Urea glucokinase activators
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
WO2007110364A1 (en) 2006-03-28 2007-10-04 High Point Pharmaceuticals, Llc Benzothiazoles having histamine h3 receptor activity
WO2007123581A1 (en) 2005-11-17 2007-11-01 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
WO2007137968A1 (en) 2006-05-29 2007-12-06 High Point Pharmaceuticals, Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
WO2008059025A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
WO2008059026A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
JP2010013472A (en) * 2009-09-09 2010-01-21 Faes Farma Sa POLYMORPH OF 4-[2-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL]-1-PIPERIDINYL] ETHYL-alpha,alpha-DIMETHYL BENZENOACETIC ACID
EP2233470A1 (en) 2005-07-04 2010-09-29 High Point Pharmaceuticals, LLC Histamine H3 receptor antagonists
EP2298337A2 (en) 2003-12-09 2011-03-23 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
WO2011104379A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
WO2011117415A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
EP2444397A1 (en) 2004-01-06 2012-04-25 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
WO2012130866A1 (en) 2011-03-28 2012-10-04 Novo Nordisk A/S Novel glucagon analogues
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
US9474790B2 (en) 2013-04-18 2016-10-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
WO2018167194A1 (en) 2017-03-15 2018-09-20 Novo Nordisk A/S Bicyclic compounds capable of binding to melanocortin 4 receptor
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019702A1 (en) * 1990-06-14 1991-12-26 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
WO1997027191A1 (en) * 1996-06-19 1997-07-31 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
WO1997031907A1 (en) * 1996-02-28 1997-09-04 Glaxo Group Limited Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma
WO1997033878A1 (en) * 1996-03-13 1997-09-18 Rhodia Chimie Improved method for preparing 3-(10-phenothiazyl)propanoic or 3-(10-phenoxazyl)propanoic acid derivatives
US5700820A (en) * 1996-02-20 1997-12-23 Dr. Reddy's Research Foundation Polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999020614A1 (en) * 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO1999038850A1 (en) * 1998-01-29 1999-08-05 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019702A1 (en) * 1990-06-14 1991-12-26 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5700820A (en) * 1996-02-20 1997-12-23 Dr. Reddy's Research Foundation Polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
WO1997031907A1 (en) * 1996-02-28 1997-09-04 Glaxo Group Limited Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma
WO1997033878A1 (en) * 1996-03-13 1997-09-18 Rhodia Chimie Improved method for preparing 3-(10-phenothiazyl)propanoic or 3-(10-phenoxazyl)propanoic acid derivatives
WO1997027191A1 (en) * 1996-06-19 1997-07-31 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999038850A1 (en) * 1998-01-29 1999-08-05 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999020614A1 (en) * 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GIRON ET AL: "Thermal analysis and calorimetric methods in the characterisation of polymorphs and solvates", THERMOCHIMICA ACTA,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 248, no. 248, pages 1-59-59, XP002101808, ISSN: 0040-6031 *
THRELFALL ET AL: "Analysis of Organic Polymorphs", ANALYST,GB,LONDON, vol. 120, no. 120, pages 2435-2460-2460, XP002101807 *

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634605A2 (en) 2000-03-08 2006-03-15 Novo Nordisk A/S Treatment of dyslipidemia in a patient having type 2 diabetes
WO2002062772A1 (en) * 2001-02-05 2002-08-15 Dr. Reddy's Research Foundation Salts of 3-4(4-(2-phenoxazin- or phenothiazin-10-yl)alkoxy)phenyl)-2-alkoxypropanoic acid derivatives with ppar activity for the treatment of hyperlipimedia and type ii diabetes
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
EP2305648A1 (en) 2001-12-21 2011-04-06 Novo Nordisk A/S Amide derivatives useful as glucokinase activators
JP2005529120A (en) * 2002-04-19 2005-09-29 ファエス・ファルマ・ソシエダッド・アノニマ 4- [2- [1- (2-Ethoxyethyl) -1H-benzimidazol-2-yl] -1-piperidinyl] ethyl] -α, α-dimethylbenzenoacetic acid polymorph
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
EP2471533A1 (en) 2002-06-27 2012-07-04 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
WO2004101505A1 (en) 2003-05-14 2004-11-25 Novo Nordisk A/S Novel compounds for treatment of obesity
WO2005030797A2 (en) 2003-09-30 2005-04-07 Novo Nordisk A/S Melanocortin receptor agonists
EP2298337A2 (en) 2003-12-09 2011-03-23 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
EP2444397A1 (en) 2004-01-06 2012-04-25 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
WO2005105785A2 (en) 2004-05-04 2005-11-10 Novo Nordisk A/S Indole derivatives for treatment of obesity
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
WO2006053906A1 (en) 2004-11-22 2006-05-26 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
WO2006058923A1 (en) 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
EP2386554A1 (en) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Compounds active at the histamine H3 receptor
EP2233470A1 (en) 2005-07-04 2010-09-29 High Point Pharmaceuticals, LLC Histamine H3 receptor antagonists
EP2377856A1 (en) 2005-07-14 2011-10-19 Novo Nordisk A/S Urea glucokinase activators
WO2007006814A1 (en) 2005-07-14 2007-01-18 Novo Nordisk A/S Urea glucokinase activators
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
WO2007123581A1 (en) 2005-11-17 2007-11-01 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
WO2007110364A1 (en) 2006-03-28 2007-10-04 High Point Pharmaceuticals, Llc Benzothiazoles having histamine h3 receptor activity
WO2007137968A1 (en) 2006-05-29 2007-12-06 High Point Pharmaceuticals, Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
EP2402324A1 (en) 2006-05-29 2012-01-04 High Point Pharmaceuticals, LLC Benzodioxolylcyclopropylpiperazinylpyridazines
WO2008059026A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
WO2008059025A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
JP2010013472A (en) * 2009-09-09 2010-01-21 Faes Farma Sa POLYMORPH OF 4-[2-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL]-1-PIPERIDINYL] ETHYL-alpha,alpha-DIMETHYL BENZENOACETIC ACID
WO2011104379A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
WO2011117416A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
WO2011117415A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
WO2012130866A1 (en) 2011-03-28 2012-10-04 Novo Nordisk A/S Novel glucagon analogues
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
US9486505B2 (en) 2011-09-23 2016-11-08 Novo Nordisk A/S Glucagon analogues
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
US9474790B2 (en) 2013-04-18 2016-10-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US9751927B2 (en) 2013-04-18 2017-09-05 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
WO2018167194A1 (en) 2017-03-15 2018-09-20 Novo Nordisk A/S Bicyclic compounds capable of binding to melanocortin 4 receptor
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Also Published As

Publication number Publication date
AU3831300A (en) 2000-11-02
BR0010683A (en) 2003-07-01
EE200100529A (en) 2002-12-16
IL145958A0 (en) 2002-07-25
BG106022A (en) 2002-04-30
HUP0200758A3 (en) 2003-07-28
RU2001130883A (en) 2004-03-20
EP1171430A1 (en) 2002-01-16
CZ20013711A3 (en) 2002-07-17
HRP20010748A2 (en) 2003-02-28
MXPA01010472A (en) 2002-05-06
NO20015016L (en) 2001-12-11
CA2370401A1 (en) 2000-10-26
CN1351597A (en) 2002-05-29
NO20015016D0 (en) 2001-10-15
HUP0200758A2 (en) 2002-07-29
TR200103851T2 (en) 2002-04-22
PL351492A1 (en) 2003-04-22

Similar Documents

Publication Publication Date Title
WO2000063192A1 (en) Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
JP2003508348A (en) Novel polymorphic forms of antidiabetic agents: methods for their preparation and pharmaceutical compositions containing them
WO2000063193A1 (en) Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
ZA200106994B (en) Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical composition containing them.
EP1322647A1 (en) Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt and process for their preparation
US6528507B1 (en) Polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
US6897199B2 (en) Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
WO2002028857A1 (en) Polymorphs of pioglitazone hydrochloride and their use as antidiabetics
US20040068116A1 (en) Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
EP1363913A2 (en) Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
US20020169175A1 (en) Pharmaceutically acceptable salts of heterocyclic compounds
EP1623984A1 (en) Polymorphic form I of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt
WO2002030914A1 (en) Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them
AU2001291232A1 (en) Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
WO2003066612A1 (en) Novel polymorphic forms of bicyclic antidiabetic agents: process for their preparation and pharmaceutical compositions containing them
AU2001291232B2 (en) Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
CN114377136A (en) Combined medicine for treating hyperlipemia and its use
WO2003006022A1 (en) Tetrahydroquinoline derivatives and their use in medicine, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2000 550843

Country of ref document: US

Date of ref document: 20000417

Kind code of ref document: A

Ref document number: 2000 551228

Country of ref document: US

Date of ref document: 20000417

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 00807705.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PV2001-3711

Country of ref document: CZ

Ref document number: P20010748A

Country of ref document: HR

ENP Entry into the national phase

Ref document number: 2370401

Country of ref document: CA

Ref document number: 2370401

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 106022

Country of ref document: BG

Kind code of ref document: A

Ref document number: 2000 612284

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14822001

Country of ref document: SK

Ref document number: PA/a/2001/010472

Country of ref document: MX

Ref document number: 1020017013208

Country of ref document: KR

Ref document number: 38313/00

Country of ref document: AU

Ref document number: P-728/01

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: 2000917222

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 515338

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001/03851

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1020017013208

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000917222

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2002 142857

Country of ref document: US

Date of ref document: 20020509

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: PV2001-3711

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2002 209567

Country of ref document: US

Date of ref document: 20020730

Kind code of ref document: A

Ref document number: 2002 217593

Country of ref document: US

Date of ref document: 20020730

Kind code of ref document: A

WWR Wipo information: refused in national office

Ref document number: PV2001-3711

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000917222

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017013208

Country of ref document: KR

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)